Cardio Diagnostics Holdings, Inc.
CDIOW
NASDAQ Global Market0.02
USD
+0.00
- -
CIK
0001870144
ISIN
US14159C1119
CUSIP
14159C111
Return %
Stock
S&P500
1Y
5.59
26.53
3Y
-85.83
76.60
5Y
-94.85
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Meeshanthini V. Dogan
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 400 N Aberdeen St Chicago IL United States of America 60642
- IPO Date
- Jan 14, 2022
- CIK
- 0001870144
- Website
- cardiodiagnosticsinc.com
- Similar Companies
- Business
- Cardio Diagnostics Holdings, Inc. is a biotechnology company specializing in AI-driven precision cardiovascular medicine with a focus on developing and commercializing epigenetic and genetic-based clinical tests for cardiovascular disease risk assessment, detection, management, and monitoring. Its main products include Epi+Gen CHD, a symptomatic coronary heart disease (CHD) risk assessment clinical blood test; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for detecting coronary heart disease; and Actionable Clinical Intelligence, a platform that provides personalized insights by linking biomarkers evaluated by these tests to the underlying drivers of CHD. The company serves healthcare providers and patient populations via partnerships with a broad network of healthcare practices including concierge, functional medicine, direct primary care, and primary care models across the United States and Puerto Rico. Headquartered in Chicago and founded in 2017, Cardio Diagnostics operates primarily in the U.S. market. Recently, Cardio Diagnostics expanded its provider network by adding 15 new healthcare organizations nationwide to broaden adoption of its AI-driven cardiovascular tests, spanning diverse care models and regions including the Northeast, South, Midwest, West, and Puerto Rico. The company also secured final Medicare pricing determinations for its Epi+Gen CHD and PrecisionCHD tests from the Centers for Medicare and Medicaid Services (CMS), affirming reimbursement for its advanced cardiovascular diagnostic tools. In 2024, Cardio Diagnostics entered a strategic partnership with digital health platform Navierre, enhancing telehealth access for its cardiovascular tests, with a focus on underserved and remote communities. Additionally, the company completed a 1-for-30 reverse stock split in 2025 to regain compliance with Nasdaq listing requirements. Cardio Diagnostics continues to integrate AI and epigenetics in cardiovascular diagnostics and expand market access through strategic partnerships and healthcare network growth.